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Summary The influence of liver biochemistry tests on epirubicin pharmacokinetics has been investigated in 52
women with advanced breast cancer, 27 of whom had radiologically proven liver metastases. Patients received
epirubicin 12.5-120mg m2 given as an i.v. bolus. Epirubicin levels were measured by HPLC following the
first cycle of treatment. Epirubicin elimination, expressed as clearance (dose/AUC), in the 22 patients with
normal AST and bilirubin was compared with that of 30 patients with a raised AST±raised bilirubin.
Epirubicin clearance was significantly reduced in the patients with a raised AST, whether their serum bilirubin
was normal (22 patients) or elevated (eight patients). In the 30 patients with a raised AST± raised bilirubin,
epirubicin clearance correlated strongly with the level of AST (r = - 0.72) but not with serum bilirubin,
alkaline phosphatase, albumin or creatinine. Using a multiple regression analysis, AST was the only one of
these biochemical variables predictive ofepirubicin clearance (r2 = 0.47, P= 0.0006). We conclude that a raised
serum AST is a more sensitive and reliable measure of abnormal epirubicin pharmacokinetics than increased
bilirubin. These findings have implications for anthracycline treatment in patients with abnormal liver
biochemistry.
The anthracyclines are amongst the most active and widely
used cytotoxic agents. The liver is the main route of elimina-
tion for these drugs of which doxorubicin was the first to be
introduced into clinical practice. Epirubicin (4'-epidoxorubi-
cin) is structurally closely related to doxorubicin, differing
only by the orientation of the C-4'-hydroxyl group on the
daunosamine sugar. This difference has an important effect
on the metabolism of epirubicin (Figure 1). Glucuronides are
formed with epirubicin at the 4' position in man (Weenan et
al., 1983; Robert et al., 1985) although not in other species
(Maessen et al., 1987). By contrast, glucuronidation is not
important in the metabolism of doxorubicin (Mross et al.,
1988). Epirubicin is metabolised more rapidly than doxoru-
bicin and at equimolar doses is less toxic (Brambilla et al.,
1986).
The effect of abnormal liver biochemistry on the toxicity
and pharmacokinetics of epirubicin was first described by
Camaggi et al. (1982) in six patients with liver metastases.
Epirubicin clearance was reduced in these patients, but this
did not correlate with any single liver biochemistry test.
Similar findings were described in other small studies (Cam-
aggi et al., 1986; 1988; Robert et al., 1985; Speth et al., 1986)
and the dose reductions of up to 75% based on serum
bilirubin recommended by Camaggi et al. (1982) in patients
with liver metastases were widely adopted (Pharmorubicin
data sheet, Farmitalia Carlo Erba). Nevertheless, the poor
correlation between liver biochemistry tests and anthracycline
clearance has made the optimal use of the drugs difficult in
patients with impaired liver function. Empirical dose adjust-
ments may lead to ineffective treatment for some patients
whilst exposing others to unacceptable toxicity.
This report describes in detail the relationship between
epirubicin pharmacokinetics and liver biochemistry tests in a
large, well defined group of patients with advanced breast
cancer who received epirubicin as a single agent. The liver
biochemistry tests used were those which are routinely avail-
able in this Unit.
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Materials and methods
Patients and treatment
Epirubicin pharmacokinetics were studied in a total of 52
women with advanced breast cancer. Patients had received
no prior anthracycline treatment and pharmacokinetics
studies were performed only during their first cycle ofchemo-
therapy. None of the patients were taking drugs known to
affect hepatic blood flow or drug metabolism. Treatment was
given between 9.00 and 15.00 h in all cases. All patients gave
written informed consent to participate in the study.
The characteristics of the patients are shown in Table I.
Patients were divided into three separate groups according to
their serum aspartate transaminase (AST) and bilirubin for
two reasons. Firstly, AST has been shown to be the single
Figure 1 Metabolism of epirubicin and doxorubicin.
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best biochemical factor predicting survival in these patients
(O'Reilly et al., 1990). Secondly, bilirubin is the basis of the
currently recommended dose modifications (Pharmorubicin
data sheet, Farmitalia Carlo Erba). Serum alkaline phospha-
tase was not used to define these groups since 36 patients had
bone scans suggestive of metastatic disease. The three patient
groups were as follows:
Group 1 - serum AST and bilirubin both within normal
limits (22 women)
Group 2 - serum AST above the upper limit of normal
but a normal serum bilirubin (22 women)
Group 3 - serum AST raised and bilirubin above the
upper limit of normal (eight women)
Patients in group 1 were sampled after epirubicin 12.5-120
mg m-2 given as a bolus intravenous (i.v.) injection. Patients
who received epirubicin 120 mgm2 were treated on a high
dose epirubicin protocol (Carmo-Pereira et al., 1991). For the
remaining patients in group 1, who received epirubicin
12.5-90 mgm-2 as an i.v. bolus, the dose of chemotherapy
was chosen on a random basis. The effects of treatment dose
and other patient related parameters on epirubicin pharma-
cokinetics in this group of patients who had normal liver
biochemistry tests, will be presented separately (Dobbs et al.,
in preparation). Patients in whom the pharmacokinetics of
the lower doses of epirubicin were being studied received the
'study' dose on day 1; where this dose was considered thera-
peutically inadequate the remainder of the treatment dose
was given 48 h later, after completing the pharmacokinetic
sampling. Subsequent chemotherapy cycles were given at
standard doses as a single bolus injection every 3 weeks. The
majority of patients in groups 2 and 3 received epirubicin
25 mg m-2 as an i.v. bolus given weekly. Most of the patients
in groups 2 and 3 were included in a clinical study of weekly
epirubicin in women with breast cancer and liver metastases
the results of which have been published previously (Twelves
et al., 1991).
Liver scans are not carried out routinely in this Unit, but
were undertaken in any patients with hepatomegaly or eleva-
tion of serum AST or bilirubin. Liver biopsies were not
performed to confirm histologically the diagnosis of hepatic
metastases.
Pharmacokinetics
Blood samples were taken from an indwelling venous can-
nula over the 48 h following chemotherapy. Samples were
collected before treatment and at 6, 12, 15, 20, 30 and
45 min, then at 1, 2, 4, 8, 24, 30 and 48 h after the start of
administration of epirubicin. Each 7 ml sample was taken
into a lithium heparin tube and centrifuged, after which the
separated plasma was stored at - 20°C. Plasma levels of
epirubicin and its six metabolites were measured by high-
performance liquid chromatography (Dobbs & Twelves,
1991) using pure analytic standards provided by Farmitalia
Carlo Erba (Milan, Italy). With this assay mean recovery of
epirubicin is 83%, and recovery of its metabolites is 51-
88%. The routine detection limit of the assay is 1 ngml- for
epirubicin, and for the metabolites ranges from 0.5-1.0 ng
ml- . The within-day and day-to-day precision of the assay,
as indicated by the coefficients of variation, are less than 8%
both for epirubicin and for its metabolites measured over a
wide range of concentrations.
Epirubicin pharmacokinetics were fitted to a 3-compart-
ment model. The 'Pharmkit' programme (Johnson et al.,
1983) was used to obtain the area under the concentration-
time curve to infinity (AUCi), the early (a), intermediate (f)
and terminal half lives. The volume of distribution (Vd) and
mean retention time (MRT), which is a measure of the
period a molecule remains in the body, were also calculated
using 'Pharmkit'. The elimination ofepirubicin was expressed
as drug clearance (dose/AUCi).
Statistics
The biochemical and pharmacokinetic parameters were com-
pared between pairs of the three groups of patients using the
Mann-Whitney test. The extent of the relationship between
each liver biochemistry test and the pharmacokinetic para-
meters was measured using Pearson's correlation. Those bio-
chemical values which showed a logarithmic distribution
were expressed on a loglo scale. Although correlation coeffic-
ients, r, as low as 0.3 are statistically significant in this data
set, they represent very weak relationships. In the current
study a correlation coefficient of 0.3 indicates that less than
10% of the variability of a pharmacokinetic value can be
attributed to a biochemical parameter and that the correla-
tion is of no predictive value. Therefore, only values of
r>0.5 were considered to have potentially important predic-
tive use, and r>0.7 was considered as showing a strong
correlation relationship since at least 25% and 50% respec-
tively of the variability is accounted for in such cases. A
multivariate step-wise linear regression was used to evaluate
the relative contribution of each biochemical test to the
variability in the pharmacokinetic values.
Results
The analysis was undertaken in three stages. Firstly, the liver
biochemistry tests of the three groups were compared.
Secondly, a comparison was made of the pharmacokinetic
parameters in the three groups. Finally we investigated the
correlation between each liver biochemistry test and the
pharmacokinetic parameters in the 22 patients with normal
liver biochemistry and in the 30 with a raised AST with or
without an elevated serum bilirubin.
Comparison ofliver biochemistry tests
The clinical and biochemical characteristics of the patients in
each of the three groups compared in Table I. None of the
four women in group 2 with an elevated serum AST in whom
liver metastases were not detected radiologically gave a his-
tory of alcohol abuse or chronic liver disease. There was no
difference in age or serum creatinine between the three
groups (P>0.5). By definition, all the patients in groups 2
and 3 had a raised AST. However, serum AST was higher in
the group 3 patients, whose serum bilirubin was also elevat-
ed, than it was in those of group 2 (P = 0.05). The group 1
patients with a normal AST and bilirubin had a higher
median serum albumin (P = 0.003) and lower alkaline phos-
phatase (P<0.001) than the patients in groups 2 and 3.
Comparison ofpharmacokinetic parameters
Epirubicin clearance for patients in the three groups is shown
in Figure 2. The remaining pharmacokinetic parameters are
shown in Table II.
The patients in group 2, with a raised AST but normal
bilirubin, had a median epirubicin clearance which was signi-
ficantly lower than that for the group 1 patients in whom
both the serum bilirubin and AST were normal (P = 0.005).
the a- and P-half lives for the groups did not differ (P= 0.78
and P = 0.53 respectively). The terminal half life was, how-
ever, significantly longer in the patients with a raised AST
than in those with normal liver biochemistry (P = 0.05).
There was a trend for MRT to be longer in group 2 than in
group 1, but this did not reach statistical significance (P =
0.07). There was no significant difference in Vd (P= 0.IO)
between the two groups.
The patients in group 3, with values of both AST and
bilirubin above the normal range, had a median epirubicin
clearance significantly lower than that of patients in group 1
(P=0.004), but similar to that of patients in group 2
(P = 0.25). There was no difference in the a- and P-half life
between patients in groups 1 and 3 (P= 0.76 and P= 0.13
respectively), but the patients in group 3 had significantlyEPIRUBICIN PHARMACOKINETICS AND LIVER BIOCHEMISTRY 767
Table I Patient characteristics and biochemistry
Group I Group 2 Group 3
Number ofpatients 22 22 8
Median age (years) 57 57 60
(range 37-77) (37-72) (43-72)
Median serum AST 21 93 175
(normal <43 unitsl-') (range 7-33) (43-489) (48-368)
Median serum bilirubin 6 9 47
(normal <23 lumol I) (range 1-15) (1-21) (23-224)
Median serum alkaline
phosphatase 196 575 1001
(normal <255 units1-') (range 65-479) (174-1789) (262-2972)
Median serum albumin 41 36 31
(normal 30-46gl-') (range 31-47) (19-44) (30-41)
Median creatinine 77 84 85
(normal 50-130 igml) (range 64-98) (67-143) (56-118)
Liver metastases 1 18 8
(radiologically proven)
ECOG performance status
0 7 2 0
1 6 10 0
2 8 8 8
3 1 2 0
Epirubucin dose
12.5mgm-2 4 3
25.0mgm-2 2 17 8
50.0 mg m-2 3 1
75.0mgm-2 4
90.0mgm-2 3 1
120.0mgm-2 6
61
51
E
41
G) O 31 c
co
a)
( ) 1
11
S.
1- 0
*
*
0
I .
2 3
Group
Figure 2 Epirubicin clearance in patients with normal AST and
bilirubin (group 1), with raised AST but normal bilirubin (group
2) and raised AST and raised bilirubin (group 3). Median
value =
Table II Pharmacokinetic parameters of groups 1, 2 and 3
Group I Group 2 Group 3
Median clearance 25.0 17.1 12.2
(ml min- I m-2) (range 13.4-59.7) (2.1 -34.1) (2.7-26.7)
Median a-tj 0.049 0.056 0.057
(h) (range 0.03-0.22) (0.39-4.01) (9.12-57.8)
Median P-t' 1.28 1.17 0.33
(h) (range 0.39-4.01) (0.31-2.66) (0.13-0.86)
Median v-ti 22.7 31.5 49.8
(h) (range 9.12-57.8) (12.4-138) (34.7- 138.6)
Median Vd 1602 1232 1302
(1) (range 135-3461) (432-2730) (799-2765)
Median MRT 24.4 36.0 72.0
(h) (range 9.1-70.2) (12.7-199) (32-179)
longer terminal half lives (P = 0.002). Mean retention time
was significantly longer in the patients of group 3 than in
group 1 (P = 0.006). The Vd for epirubicin was the same for
groups 1 and 3 (P=0.12).
Correlation between liver biochemistry tests and
pharmacokinetic parameters
Despite the relatively wide range of values for epirubicin
clearance in the patients with normal AST and bilirubin
(group 1), there was no significant relationship between clear-
ance and loglo serum AST (r = - 0.25), bilirubin (r= - 0.03),
alkaline phosphatase (r = - 0.09) or albumin (r =-0.29) or
creatinine (r = - 0.20) within this group.
For the 30 patients with a raised AST irrespective of the
level of serum bilirubin (groups 2 and 3), there was a strong
correlation between clearance and loglo AST (Figure 3;
r= - 0.72). Epirubicin clearance was not significantly cor-
related with logio serum bilirubin (r = 0.37), alkaline phos-
phatase (r = 0.47), albumin (r= 0.06) or creatinine (r = 0.16).
In a linear multiple regression analysis serum AST was the
only one of these biochemical variable which was predictive
of epirubicin clearance (r2 = 47.99; P = 0.0006).
The effect of AST on epirubicin pharmacokinetics was
investigated further by studying its correlation with other
pharmacokinetic parameters. Loglo AST correlated strongly
with the terminal half-life (Figure 4; r = 0.75) and MRT
(r = 0.85). There was no correlation between AST and Vd
(r = - 0.35), a-half life (r =-0.26) or P-half life (r = 0.21).
Discussion
Despite the widespread use of anthracyclines, the role of the
liver in eliminating these drugs and the frequent occurrence
of liver metastases from solid tumours, the evidence that
pharmacokinetics are altered and dose modifications are
needed in patients with deranged liver function has been
inconclusive. A report by Benjamin et al. in 1973 had an
important impact on dosage strategies for anthracyclines in
patients with abnormal liver biochemistry. Benjamin et al.
(1973) described increased toxicity in eight patients with liver
metastases who were treated with doxorubicin, although the
r
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study was serum AST, an enzyme normally located in the
microsomal membrane of hepatocytes but also widely distri-
buted in other tissues. The finding that AST correlates with
terminal half-life, in addition to clearance and MRT, is
consistent with the suggestion that hepatocyte damage direct-
ly or indirectly influences the elimination of epirubicin in
these patients. The level of AST is a more sensitive and
reliable measure of the effect of liver dysfunction on epiru-
bicin pharmacokinetics than other conventional liver bio-
chemistry tests, including serum bilirubin.
The findings in the current study, taken with published
reports for doxorubicin, suggest that the effect of abnormal
liver biochemistry on the pharmacokinetics ofepirubicin and
AST doxorubicin differ substantially. Although the two com-
re 3 Correlation between epirubicin clearance and loglo pounds are structurally very similar, the orientation of the
in patients with raised AST±raised bilirubin. -OH group at the C-4' position on the daunosamine sugar
leads to extensive glucuronidation of epirubicin and its
reduced metabolite epirubicinol. In comparative studies gluc-
uronides were detected in the plasma and urine of patients
when treated with epirubicin, but not doxorubicin (Mross et
al., 1988; Camaggi et al., 1988). Therefore, although both
epirubicin and doxorubicin are eliminated by the liver, only
epirubicin also undergoes extensive hepatic metabolism.
Impairment of this glucuronidation pathway in patients with
deranged liver biochemistry may be the reason for the rela-
r= 0.75 . tionship between drug clearance and serum AST. Glucuroni-
dation is an important pathway for the biotransformation of
many drugs. Hoyumpa and Schenker (1991) have reviewed
the evidence that glucuronidation of drugs may be impaired
in some patients with liver disease. That this may be so for
epirubicin is also supported by the finding of Robert et al.
2.1 *,(1990) that a low ratio of epirubicin glucuronide to epiru-
63 126 251 501 1000 bicin concentrations was associated with reduced plasma
AST fibrinogen and alpha 2-globulin levels. These plasma proteins
re 4 Correlation between terminal half-life and loglo AST in may reflect hepatocellular insufficiency, but details of conven-
ints with raised AST±raised bilirubin. tional liver biochemistry tests were not given. We are under-
taking further studies of epirubicin metabolism in relation to
a range of liver biochemistry tests.
An important question raised by this study is that of
rbances of liver biochemistry were not described in whether, and how, dosage adjustments should be made when
and pharmacokinetic data were presented from only using epirubicin to treat patients who have abnormal liver
atients. The dose reductions they recommended, on the biochemistry. This question has not been answered satisfac-
of a raised serum bilirubin, were widely adopted torily by early reports (Camaggi et al., 1982; 1986; Robert et
iamycin data sheet, Farmitalia Carlo Erba) although al., 1985; Speth et al., 1986). The current study has clearly
were never validated. Indeed, subsequent reports failed demonstrated a relationship between liver biochemistry, in
Infirm a close relationship between abnormal liver bio- particular AST, and epirubicin pharmacokinetics. The study
istry and either clinical toxicity or pharmacokinetic design, with weekly low dose chemotherapy for most
neters in patients receiving doxorubicin (Brenner et al., patients, and split-dose treatment for many others, precludes
Preisler et al., 1984; Preiss et al., 1987; Frenay et al., an evaluation of the relationship between liver biochemistry,
l. epirubicin pharmacokinetics and treatment toxicity or effic-
ien epirubicin was introduced, Camaggi et al. (1982) acy. However, other studies attempting to relate anthracyc-
ibed reduced clearance in patients with liver metastases line kinetics with treatment efficacy and toxicity have had
ith biliary obstruction (Camaggi et al., 1986). As a some success. High doxorubicin levels were associated with
;, the dosage reductions recommended for epirubicin prolonged remission duration in patients with acute nonlym-
morubicin data sheet, Farmitalia Carlo Erba) were phocytic leukaemia (Preisler et al., 1984). Similarly, Robert et
ir to those for doxorubicin. Several studies have failed, al. (1983) correlated early phase doxorubicin pharmaco-
ver, to demonstrate a consistent relationship between kinetics with response in patients with breast cancer. In
bicin clearance and liver biochemistry tests (Camaggi et relation to treatment toxicity, raised serum transaminases
982; Robert et al., 1985; Speth et al., 1986). These predicted reduced efficacy of scalp cooling in preventing
as reported only small numbers ofpatients from a heter- alopecia for patients treated with epirubicin (Robinson et al.,
bous population and the nature of the abnormalities of 1987). These data suggest that there may be a relationship
biochemistry were not well defined. Because of the between anthracycline pharmacokinetics and treatment out-
tainty regarding the effect of liver dysfunction on epiru- come although this needs clarification.
pharmacokinetics, such dose modifications have been Definitive dosage recommendations for patients with ab-
oversial and different dosage strategies have been adopt- normal liver biochemistry will depend on demonstrating a
lamaggi et al., 1982; Twelves et al., 1991). relationship between liver dysfunction and epirubicin phar-
i most important finding of the current study is that a macodynamics. Nevertheless it is apparent that serum AST
y available liver biochemistry test reflects consistent rather than bilirubin may be the best indicator for dose
yes in epirubicin pharmacokinetics. The relationship was adjustments. In this respect, there appears to be an important
gest for epirubicin clearance which is the best pharma- distinction between these two anthracyclines (Dobbs et al.,
etic measure ofhepatic metabolism (Perrier & Grimaldi, 1991) with the possibility that rational dosage adjustments in
Conventional liver biochemistry tests, such as those the face of abnormal liver biochemistry may be more easily
[bed in this study, reflect hepatocyte damage and gener- made for epirubicin than for doxorubicin.
iave no functional significance. The parameter which In summary, we have demonstrated a significant, quantita-
lated most strongly with epirubicin clearance in this tive relationship between serum AST and both epirubicin
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clearance and MRT. This is due to prolongation of the
terminal half-life of epirubicin in patients with a raised AST
and may reflect impaired glucuronidation. These findings
have potentially important implications for the treatment of
patients with disturbed liver biochemistry. Firstly, in patients
treated with epirubicin, AST measurements provide a more
rational basis for dose reductions than the currently recom-
mended use of serum bilirubin. Secondly, because the rela-
tionship between pharmacokinetic parameters and liver
biochemistry tests is more predictive with epirubicin, this
drug may be preferable to doxorubicin in these patients.
This study was supported by the Hans Oppenheimer Trust and
Farmitalia Carlo Erba.
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